Atsena Therapeutics is a clinical-stage gene therapy company that is dedicated to using the power of genetic medicine to reverse or prevent blindness. Their pipeline of clinical and preclinical assets is focused on overcoming the challenges presented by inherited retinal diseases. Atsena's approach for each program is tailored to meet the specific needs of patients with these conditions.

Led by experts in AAV gene therapy, ophthalmology, and CMC, Atsena is advancing programs in X-linked retinoschisis, Leber congenital amaurosis 1, and Usher syndrome 1B. They are currently conducting Phase I/II clinical trials for their X-linked retinoschisis and Leber congenital amaurosis 1 programs. Additionally, they are making rapid progress in evaluating a dual AAV vector-based gene therapy for Usher syndrome 1B.

Founded by renowned ocular gene therapy pioneers from the University of Florida, Atsena is committed to improving the quality of life for patients with inherited retinal diseases through the discovery and development of gene therapies. With a focus on patients and families, a dedication to science, and responsible stewardship, Atsena is striving to make targeted solutions for ocular diseases a reality